SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 592.91 |
| Enterprise Value ($M) | 318.09 |
| Book Value ($M) | 350.07 |
| Book Value / Share | 6.41 |
| Price / Book | 1.69 |
| NCAV ($M) | 318.92 |
| NCAV / Share | 5.84 |
| Price / NCAV | 1.86 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.14 |
| Return on Assets (ROA) | 0.25 |
| Return on Equity (ROE) | 0.36 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 8.41 |
| Current Ratio | 8.41 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 375.74 |
| Assets | 406.89 |
| Liabilities | 56.81 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 36.55 |
| Operating Income | -101.37 |
| Net Income | -88.98 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -86.85 |
| Cash from Investing | -107.47 |
| Cash from Financing | 131.09 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 5.80 | -42.34 | |
| 13G | BlackRock Portfolio Management LLC | 5.10 | ||
| 13G/A | Rtw Investments, Lp | 9.99 | 28.54 | |
| 13G/A | Morgan Stanley | 6.50 | 2.04 | |
| 13D/A | Skorpios Trust | 13.00 | -22.46 | |
| 13G/A | Lynx1 Capital Management LP | 9.90 | 75.43 | |
| 13G/A | Redmile Group, LLC | 9.00 | 79.53 | |
| 13G | Baker Bros. Advisors Lp | 8.30 | ||
| 13G/A | Vanguard Group Inc | 5.24 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 56,584 | 311,029 | 18.19 | |
| 165,354 | 540,830 | 30.57 | |
| 354,961 | 1,276,036 | 27.82 | |
| 90,024 | 446,806 | 20.15 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SPRO – Spero Therapeutics, Inc. | SRPT – Sarepta Therapeutics, Inc. |
| SRRK – Scholar Rock Holding Corporation | STTK – Shattuck Labs, Inc. |
| SVRA – Savara Inc. |
Financial data and stock pages provided by
Fintel.io